Medscape: Triple cytokine scaffold builds long-lived CAR T cells against HIV
Researchers are testing a new 'triple cytokine scaffold' to improve the longevity and efficacy of CAR T-cell therapy in treating HIV. The study aims to overcome the historical challenge of engineered immune cells failing to persist long enough to eliminate the virus.
Why it matters
This research represents a potential breakthrough in HIV treatment, moving beyond current antiretroviral therapies toward a more durable, cell-based approach.
For 25 years, researchers have engineered immune cells to hunt down HIV. The approach, known as chimeric antigen receptor (CAR) T-cell therapy, extracts a patient’s T cells, engineers them to recognize a specific target on infected cells, and infuses them back into the patient. The engineered cells circulate, find their target, and kill. In fact, the challenge has never actually been about whether a target could be killed; it lies in getting the newly engineered cells to last long enough to finish the job.
The article provides a scientific overview of medical research without bias or sensationalism.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in